Adaptive Biotechnologies Corp Insider Trading for March 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Adaptive Biotechnologies Corp.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Adaptive Biotechnologies Corp for March 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 5,290 | 33,433 | 167,485 | |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 6,395 | 40,416 | 172,775 | |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 7,790 | 49,233 | 179,170 | |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 38.72 | 1,481 | 57,344 | 69,360 | 70.8 K to 69.4 K (-2.09 %) |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 38.13 | 3,809 | 145,237 | 70,841 | 74.7 K to 70.8 K (-5.10 %) |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 5,290 | 33,433 | 74,650 | 69.4 K to 74.7 K (+7.63 %) |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 41.76 | 400 | 16,704 | 69,360 | 69.8 K to 69.4 K (-0.57 %) |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 40.33 | 4,175 | 168,378 | 69,760 | 73.9 K to 69.8 K (-5.65 %) |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 39.43 | 1,820 | 71,763 | 73,935 | 75.8 K to 73.9 K (-2.40 %) |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 6,395 | 40,416 | 75,755 | 69.4 K to 75.8 K (+9.22 %) |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 41.93 | 7,790 | 326,635 | 69,360 | 77.2 K to 69.4 K (-10.10 %) |
| Mar 25 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 7,790 | 49,233 | 77,150 | 69.4 K to 77.2 K (+11.23 %) |
| Mar 22 2021 | ADPT | Adaptive Biotechno ... | OWEN KATEY EINTERZ | Director | Option Exercise | A | 45.01 | 11,109 | 500,016 | 11,109 | |
| Mar 22 2021 | ADPT | Adaptive Biotechno ... | OWEN KATEY EINTERZ | Director | Grant | A | 0.00 | 4,443 | 0 | 4,443 | 0 to 4.4 K |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | Palaniappan Jyoti | SVP, Diagnostics, i ... | Option Exercise | M | 22.55 | 16,052 | 361,973 | 108,948 | |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | Palaniappan Jyoti | SVP, Diagnostics, i ... | Sell | S | 45.32 | 1,739 | 78,811 | 9,158 | 10.9 K to 9.2 K (-15.96 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | Palaniappan Jyoti | SVP, Diagnostics, i ... | Sell | S | 43.83 | 5,971 | 261,709 | 10,897 | 16.9 K to 10.9 K (-35.40 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | Palaniappan Jyoti | SVP, Diagnostics, i ... | Sell | S | 43.04 | 8,342 | 359,040 | 16,868 | 25.2 K to 16.9 K (-33.09 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | Palaniappan Jyoti | SVP, Diagnostics, i ... | Buy | M | 22.55 | 16,052 | 361,973 | 25,210 | 9.2 K to 25.2 K (+175.28 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 42.48 | 100 | 4,248 | 1,763,461 | 1.8 M to 1.8 M (-0.01 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 41.96 | 4,900 | 205,604 | 1,763,561 | 1.8 M to 1.8 M (-0.28 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 43.78 | 470 | 20,577 | 1,768,461 | 1.8 M to 1.8 M (-0.03 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 42.81 | 2,604 | 111,477 | 1,768,931 | 1.8 M to 1.8 M (-0.15 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 41.90 | 1,926 | 80,699 | 1,771,535 | 1.8 M to 1.8 M (-0.11 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 45.25 | 1,804 | 81,631 | 1,773,461 | 1.8 M to 1.8 M (-0.10 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 44.03 | 1,295 | 57,019 | 1,775,265 | 1.8 M to 1.8 M (-0.07 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 43.22 | 1,901 | 82,161 | 1,776,560 | 1.8 M to 1.8 M (-0.11 %) |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | Trigg Leslie | Director | Option Exercise | A | 45.01 | 11,109 | 500,016 | 11,109 | |
| Mar 19 2021 | ADPT | Adaptive Biotechno ... | Trigg Leslie | Director | Grant | A | 0.00 | 4,443 | 0 | 4,443 | 0 to 4.4 K |
| Mar 12 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 10,000 | 63,200 | 45,000 | |
| Mar 12 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 42.54 | 10,000 | 425,400 | 21,604 | 31.6 K to 21.6 K (-31.64 %) |
| Mar 12 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 10,000 | 63,200 | 31,604 | 21.6 K to 31.6 K (+46.29 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 42.38 | 30,268 | 1,282,664 | 12,309,090 | 12.3 M to 12.3 M (-0.25 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 41.47 | 25,732 | 1,067,037 | 12,339,358 | 12.4 M to 12.3 M (-0.21 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 41.16 | 34,302 | 1,411,887 | 12,365,090 | 12.4 M to 12.4 M (-0.28 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 40.42 | 215,698 | 8,719,333 | 12,399,392 | 12.6 M to 12.4 M (-1.71 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 41.62 | 85,911 | 3,575,753 | 12,615,090 | 12.7 M to 12.6 M (-0.68 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 41.21 | 71,194 | 2,933,641 | 12,701,001 | 12.8 M to 12.7 M (-0.56 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 39.97 | 33,600 | 1,343,039 | 12,772,195 | 12.8 M to 12.8 M (-0.26 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 39.22 | 75,000 | 2,941,163 | 12,805,795 | 12.9 M to 12.8 M (-0.58 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 38.22 | 234,295 | 8,954,310 | 12,880,795 | 13.1 M to 12.9 M (-1.79 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 10,000 | 63,200 | 55,000 | |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 40.79 | 2,890 | 117,883 | 21,064 | 24 K to 21.1 K (-12.06 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 40.02 | 7,110 | 284,542 | 23,954 | 31.1 K to 24 K (-22.89 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 10,000 | 63,200 | 31,064 | 21.1 K to 31.1 K (+47.47 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Option Exercise | M | 0.45 | 2,000 | 900 | 53,000 | |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Sell | S | 44.56 | 2,000 | 89,120 | 0 | 2 K to 0 (-100.00 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Buy | M | 0.45 | 2,000 | 900 | 2,000 | 0 to 2 K |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Option Exercise | M | 0.45 | 2,000 | 900 | 53,000 | |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Sell | S | 44.56 | 2,000 | 89,120 | 1,504 | 3.5 K to 1.5 K (-57.08 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Buy | M | 0.45 | 2,000 | 900 | 3,504 | 1.5 K to 3.5 K (+132.98 %) |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Option Exercise | A | 43.68 | 57,234 | 2,499,981 | 57,234 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Grant | A | 0.00 | 22,894 | 0 | 22,894 | 0 to 22.9 K |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Option Exercise | A | 43.68 | 114,469 | 5,000,006 | 114,469 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Grant | A | 0.00 | 45,788 | 0 | 45,788 | 0 to 45.8 K |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | A | 43.68 | 171,703 | 7,499,987 | 171,703 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Grant | A | 0.00 | 68,681 | 0 | 69,360 | 679 to 69.4 K (+10,115.02 %) |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Option Exercise | A | 43.68 | 34,341 | 1,500,015 | 34,341 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Grant | A | 0.00 | 13,736 | 0 | 15,036 | 1.3 K to 15 K (+1,056.62 %) |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | Palaniappan Jyoti | SVP, Diagnostics, i ... | Option Exercise | A | 43.68 | 22,894 | 1,000,010 | 22,894 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | Palaniappan Jyoti | SVP, Diagnostics, i ... | Grant | A | 0.00 | 9,158 | 0 | 9,158 | 0 to 9.2 K |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | ADAMS R MARK | EVP & Chief Operati ... | Option Exercise | A | 43.68 | 51,511 | 2,250,000 | 51,511 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | ADAMS R MARK | EVP & Chief Operati ... | Grant | A | 0.00 | 20,604 | 0 | 70,604 | 50 K to 70.6 K (+41.21 %) |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | A | 43.68 | 57,234 | 2,499,981 | 57,234 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Grant | A | 0.00 | 22,894 | 0 | 22,894 | 0 to 22.9 K |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Option Exercise | A | 43.68 | 51,511 | 2,250,000 | 51,511 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Grant | A | 0.00 | 20,604 | 0 | 20,604 | 0 to 20.6 K |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | A | 43.68 | 171,703 | 7,499,987 | 171,703 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Grant | A | 0.00 | 68,681 | 0 | 1,778,461 | 1.7 M to 1.8 M (+4.02 %) |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | A | 43.68 | 51,511 | 2,250,000 | 51,511 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Grant | A | 0.00 | 20,604 | 0 | 21,604 | 1,000 to 21.6 K (+2,060.40 %) |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | BOBULSKY SUSAN | SVP, Diagnostics, c ... | Option Exercise | A | 43.68 | 22,894 | 1,000,010 | 22,894 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | BOBULSKY SUSAN | SVP, Diagnostics, c ... | Grant | A | 0.00 | 9,158 | 0 | 9,158 | 0 to 9.2 K |
| Mar 01 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Option Exercise | M | 6.55 | 15,000 | 98,250 | 240,325 | |
| Mar 01 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Sell | S | 56.23 | 15,000 | 843,450 | 0 | 15 K to 0 (-100.00 %) |
| Mar 01 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Buy | M | 6.55 | 15,000 | 98,250 | 15,000 | 0 to 15 K |
| Mar 01 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Option Exercise | M | 6.55 | 1,771 | 11,600 | 23,021 | |
| Mar 01 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Option Exercise | M | 7.80 | 1,041 | 8,120 | 27,084 | |
| Mar 01 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Sell | S | 56.40 | 1,333 | 75,181 | 1,300 | 2.6 K to 1.3 K (-50.63 %) |
| Mar 01 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Sell | S | 55.46 | 400 | 22,184 | 2,633 | 3 K to 2.6 K (-13.19 %) |
| Mar 01 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Sell | S | 54.47 | 1,079 | 58,773 | 3,033 | 4.1 K to 3 K (-26.24 %) |
| Mar 01 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Buy | M | 6.55 | 1,771 | 11,600 | 4,112 | 2.3 K to 4.1 K (+75.65 %) |
| Mar 01 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Buy | M | 7.80 | 1,041 | 8,120 | 2,341 | 1.3 K to 2.3 K (+80.08 %) |